Soluble epoxide hydrolase and ischemic cardiomyopathy

International Journal of Cardiology

Volumn 155, Issue 2, 2012, Pages 181-187

  Zhao, Ting Ting ^a   Wasti, Binaya ^a   Xu, Dan Yan ^a   Shen, Li ^a   Du, Jian Qing ^a   Zhao, Shui Ping ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Epoxyeicosatrienoic acid; Ischemic cardiomyopathy; Soluble epoxide hydrolase

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; CALCIUM CHANNEL L TYPE; ENDOTHELIUM DERIVED HYPERPOLARIZING FACTOR; ENZYME INHIBITOR; EPOXIDE HYDROLASE; EPOXYICOSATRIENOIC ACID; PHOSPHOPROTEIN PHOSPHATASE; SOLUBLE EPOXIDE HYDROLASE; SOLUBLE EPOXIDE HYDROLASE INHIBITOR; UNCLASSIFIED DRUG;

ATHEROSCLEROSIS; CATALYSIS; CELL PROLIFERATION; CELL SURVIVAL; DRUG EFFICACY; DRUG POTENCY; ENZYME ACTIVATION; ENZYME METABOLISM; EPHX2 GENE; EXTRACELLULAR FLUID; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE PRODUCT; GENE STRUCTURE; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; HYPERPOLARIZATION; ISCHEMIC CARDIOMYOPATHY; LIPID METABOLISM; MEMBRANE STEADY POTENTIAL; NONHUMAN; OXIDATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN SYNTHESIS; PROTEIN TARGETING; QT PROLONGATION; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; UPREGULATION;

CARDIOMYOPATHIES; EPOXIDE HYDROLASES; HUMANS; MYOCARDIAL ISCHEMIA; POLYMORPHISM, GENETIC; SOLUBILITY;

EID: 84857043876     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2011.05.067     Document Type: Review

References (69)

1. S.S. Gill, B.D. Hammock, and I. Yamamoto. Preliminary chromatographic studies on the metabolites and photodecomposition products of the juvenoid 1-(4'-ethylphenoxy - 6,7-epoxy-3,7- dimethyl-2-octene J.J. Menn, M. Beroza, Insect juvenile hormones: chemistry and action 1972 Academic Press New York 177 189
2. A.J. Fretland, and C.J. Omiecinski Epoxide hydrolases: biochemistry and molecular biology Chemico-Biological Interactions 129 2000 41 59
3. S.S. Gill, and B.D. Hammock Distribution and properties of a mammalian soluble epoxide hydrase Biochem Pharmacol 29 1980 389 395
4. M. Arand, M. Knehr, H. Thomas, H.D. Zeller, and F. Oesch An impaired peroxisomal targeting sequence leading to an unusual bicompartmental distribution of cytosolic epoxide hydrolase FEBS Lett 294 1991 19 22
5. C. Morisseau, and B.D. Hammock Gerry Brooks and epoxide hydrolases: four decades to a pharmaceutical Pest Manag Sci 64 2008 594 609
6. B.D. Przybyla-Zawislak, P.K. Srivastava, and H. Vázquez- Matiás Polymorphism in human soluble epoxide hydrolase [J] Mol Pharmacol 64 2003 482 490
7. C.R. Lee, K.E. North, and M.S. Bray Genetic variation in soluble epoxide hydrolase (EPHX2) and risk of coronary heart disease: the atherosclerosis risk in communities (ARIC) study J] Hum Mol Genet 15 2006 1640 1649
8. M. Fornage, E. Boerwinkle, and P.A. Doris Polymorphism of the soluble epoxide hydrolase is associated with coronary artery calcification in African-American subjects: the Coronary Artery Risk Development in Young Adults (CARDIA) study. [J] Circulation 109 3 2004 Jan 27 335 339
9. K.P. Burdon, A.B. Lehtinen, and C.D. Langefeld Genetic analysis of the soluble epoxide hydrolase gene, ephx2, in subclinical cardiovascular disease in the diabetes heart study Diab Vasc Dis Res 5 2 2008 128 134
10. J.W. Newman, C. Morisseau, and T.R. Harris The soluble epoxide hydrolase encoded by EPXH2 is a bifunctional enzyme with novel lipid phosphate phosphatase activity [J] PNAS 100 2003 1558 1563
11. A.E. Enayetallah, A. Luria, and B. Luo Opposite regulation of cholesterol levels by the phosphatase and hydrolase domains of soluble epoxide hydrolase J] Biological Chemistry 283 52 2008 36592 36598
12. K.L. Tran Lipid sulfates and sulfonates are allosteric competitive inhibitors of the N-terminal phosphatase activity of the mammalian soluble epoxide hydrolase Biochemistry 44 2005 12179 12187
13. C. Morisseau, and B.D. Hammock Epoxide hydrolases: mechanisms, inhibitor designs, and biological roles Annu Rev Pharmacol Toxicol 45 2005 311 333
14. F. Oesch, L. Schladt, and R. Hartmann Rat cytosolic epoxide hydrolase Adv Exp Med Biol 197 1986 195 201
15. Ami oguro, Natsuko fujita, and Susumu inaoka. Regulation of Soluble Epoxide Hydrolase (sEH) in mice with diabetes: high glucose suppresses sEH expression Drug Metab Pharmacokinet 24 5 2009 438 445
16. S. Petruzzelli, M. Franchi, and L. Gronchi Cigarette smoke inhibits cytosolic but not microsomal epoxide hydrolase of human lung Hum Exp Toxicol 11 2 1992 Mar 99 103
17. J.D. Imig, X. Zhao, and J.H. Capdevila Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension Hypertension 39 2 Pt 2 2002 Feb 690 694
18. D. Ai, Y. Fu, and D. Guo Angiotensin II up-regulates soluble epoxide hydrolase in vascular endothelium in vitro and in vivo Proc Natl Acad Sci U S A 104 21 2007 May 22 9018 9023
19. F. Pinot, D.F. Grant, and J.L. Spearow Differential regulation of soluble epoxide hydrolase by clofibrate and sexual hormones in the liver and kidneys of mice Biochem Pharmacol 50 4 1995 Aug 8 501 508
20. B. Inceoglu, S.L. Jinks, and K.R. Schmelzer Inhibition of soluble epoxide hydrolase reduces LPS-induced thermal hyperalgesia and mechanical allodynia in a rat model of inflammatory pain Life Sci 79 2006 2311 2319
21. P. Luo, H.H. Chang, and Y. Zhou Inhibition or deletion of soluble epoxide hydrolase prevents hyperglycemia, promotes insulin secretion, and reduces islet apoptosis J Pharmacol Exp Ther 334 2 2010 Aug 430 438
22. A. Ulu, B.B. Davis, and H.J. Tsai Soluble epoxide hydrolase inhibitors reduce the development of atherosclerosis in apolipoprotein E-knockout mouse model J Cardiovasc Pharmacol 52 2008 314 323
23. K.R. Chaudhary, M. Abukhashim, and S.H. Hwang Inhibition of soluble epoxide hydrolase by trans-4- [4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]- benzoic acid is protective against ischemia-reperfusion injury J Cardiovasc Pharmacol 55 1 2010 Jan 67 73
24. A.A. Spector, X. Fang, and G.D. Snyder Epoxyeicosatrienoic acids (EETs): metabolism and biochemical function Prog Lipid Res 43 2004 55 90
25. Z. Yu Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids Circ Res 87 2000 992 998
26. I.H. Kim, C. Morisseau, and T. Watanabe Design, synthesis, and biological activity of 1,3-disubstituted ureas as potent inhibitors of the soluble epoxide hydrolase of increased water solubility J Med Chem 47 8 2004 Apr 8 2110 2122
27. H.J. Tsai, S.H. Hwang, and C. Morisseau Pharmacokinetic screening of soluble epoxide hydrolase inhibitors in dogs Eur J Pharm Sci 40 3 2010 Jun 14 222 238
28. F.A. Fitzpatrick, M.D. Ennis, and M.E. Baze Inhibition of cyclooxygenase activity and platelet aggregation by epoxyeicosatrienoic acids. Influence of stereochemistry J Biol Chem 261 32 1986 Nov 15 15334 15338
29. D.C. Zeldin, S. Wei, and J.R. Falck Metabolism of epoxyeicosatrienoic acids by cytosolic epoxide hydrolase: substrate structural determinants of asymmetric catalysis [J] Arch Biochem Biophys 316 1995 443 451
30. X. Fang, T.L. Kaduce, and N.L. Weintraub Pathways of epoxyeicosatrienoic acid metabolism in endothelial cells: implications for the vascular effects of soluble epoxide hydrolase inhibition J Biol Chem 276 18 2001 14867 14874
31. R.L. Widstrom, A.W. Norris, and A.A. Spector Binding of cytochrome P450 monooxygenase and lipoxygenase pathway products by heart fatty acid-binding protein Biochemistry 40 4 2001 Jan 30 1070 1076
32. X. Fang, N.L. Weintraub, and C.L. Oltman Human coronary endothelial cells convert 14,5-EET to a biologically active chain-shortened epoxide Am J Physiol Heart Circ Physiol 283 2002 H2306 H2314
33. H.C. Hercule, W.H. Schunck, and V. Gross Interaction between P450 eicosanoids and nitric oxide in the control of arterial tone in mice Arterioscler Thromb Vasc Biol 29 2009 54 60
34. A.A. Spector, and A.W. Norris Action of epoxyeicosatrienoic acids on cellular function Am J Physiol Cell Physiol 292 2007 C996 C1012
35. Y. Wang, X. Wei, and X. Xiao Arachidonic acid epoxygenase metabolites stimulate endothelial cell growth and angiogenesis via MAPK and PI3K/Akt signaling pathways J Pharmacol Exp Ther 314 2005 522 532
36. W.B. Campbell, D. Gebremedhin, and P.F. Pratt Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors [J] Circ Res 78 1996 415 423
37. M.J. Merkel, L. Liu, and Z. Cao Inhibition of soluble epoxide hydrolase preserves cardiomyocytes: role of STAT3 signaling Am J Physiol Heart Circ Physiol 298 2 2010 Feb H679 H687
38. P. Richardson, W. McKenna, and M. Bristow Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the definition and classification of cardiomyopathies Circulation 93 5 1996 Mar 1 841 842
39. B. Inceoglu, K.R. Schmelzer, and C. Morisseau Soluble epoxide hydrolase inhibition reveals novel biological functions of epoxyeicosatrienoic acids (EETs) Pros-taglandins Other Lipid Mediat 82 2007 42 49
40. K. Node, Y. Huo, and X. Ruan Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids Science 285 1999 1276 1279
41. Y. Liu, Y. Zhang, and K. Schmelzer The antiinflammatory effect of laminar flow: the role of PPARgamma, epoxyeicosatrienoic acids, and soluble epoxide hydrolase Proc Natl Acad Sci U S A 102 2005 16747 16752
42. K.R. Schmelzer, L. Kubala, and J.W. Newman Soluble epoxide hydrolase is a therapeutic target for acute inflammation Proc Natl Acad Sci U S A 102 2005 9772 9777
43. J.Y. Liu, J. Yang, and B. Inceoglu Inhibition of soluble epoxide hydrolase enhances the anti-inflammatory effects of aspirin and 5-lipoxygenase activation protein inhibitor in a murine model Biochem Pharmacol 79 6 2010 Mar 15 880 887
44. L.N. Zhang, J. Vincelette, and Y. Cheng Inhibition of soluble epoxide hydrolase attenuated atherosclerosis, abdominal aortic aneurysm formation and dyslipidemia [J]Arterioscler Thromb Vasc Biol 29 9 2009 1265 1270 Sep
45. K. Sato, M. Emi, and Y. Ezura Soluble epoxide hydrolase variant (Glu287Arg) modifies plasma total cholesterol and triglyceride phenotype in familial hypercholesterolemia: intrafamilial association study in an eight-generation hyperlipidemic kindred [J] Hum Genet 49 1 2004 29 34
46. Taeye De, B.M. Morisseau, and C. Coyle Expression and regulation of soluble epoxide hydrolase in adipose tissue [J]Obesity(Silver Spring) 18 3 2010 489 498 Mar.
47. M. Revermann, M. Schloss, and E. Barbosa-Sicard Soluble epoxide hydrolase deficiency attenuates neointima formation in the femoral cuff model of hyperlipidemic mice [J] Arterioscler Thromb Vasc Biol 11 2010 Mar
48. K.M. Gauthier, E.M. Edwards, and J.R. Falck 14,15-epoxyeicosatrienoic acid represents a transferable endothelium-dependent relaxing factor in bovine coronary arteries [J] Hypertension 45 4 2005 Apr 666 671
49. B.T. Larsen, H. Miura, and O.A. Hatoum Epoxyeicosatrienoic and dihydroxyeicosatrienoic acids dilate human coronary arterioles via BKCa channels: implicatioins of soluble epoxide hydrolase inhibition [J]Am Physiol - Heart C 290 2006 491 499
50. M. Rosolowsky, J.R. Falck, and J.T. Willerson Synthesis of lipoxygenase and epoxygenase products of arachidonic acid by normal and stenosed canine coronary arteries [J] Circ Res 66 1990 608 621
51. U.R. Michaelis, B. Fisslthaler, and E. Barbosa-Sicard Cytochrome P450 epoxygenases 2 C8 and 2 C9 are implicated in hypoxia-induced endothelial cell migration and angiogenesis J Cell Sci 118 2005 5489 5498
52. S. Suzuki, A. Oguro, and M. Osada-Oka Epoxyeicosatrienoic acids and/or their metabolites promote hypoxic response of cells J Pharmacol Sci 108 1 2008 Sep 79 88
53. A. Oguro, K. Sakamoto, and S. Suzuki Contribution of hydrolase and phosphatase domains in soluble epoxide hydrolase to vascular endothelial growth factor expression and cell growth Biol Pharm Bull 32 12 2009 Dec 1962 1967
54. J.M. Seubert, C.J. Sinal, and J. Graves Role of soluble epoxide hydrolase in postischemic recovery of heart contractile function [J] Circ Res 99 2006 442 450
55. C.J. Sinal, M. Miyata, and M. Tohkin Targeted disruption of soluble epoxide hydrolase reveals a role in blood pressure regulation [J] Biol Chem 275 2000 40504 40510
56. J. Seubert, B. Yang, and J.A. Bradbury Enhanced postischemic functional recovery in CYP2J2 transgenic hearts involves mitochondrial ATP-sensitive K + channels and p42/44 MAPK pathway [J]Circ Res 95 2004 506 514
57. M.J. Merkel, L. Liu, and Z. Cao Inhibition of soluble epoxide hydrolase preserves cardiomyocytes: role of STAT3 signaling Am J Physiol Heart Circ Physiol 298 2 2010 Feb H679 H687
58. A. Motoki, M.J. Merkel, and W.H. Packwood Soluble epoxide hydrolase inhibition and gene deletion are protective against myocardial ischemia-reperfusion injury in vivo [J] Am Physiol Heart Circ Physiol 295 5 2008 H2128 H2134 Nov
59. S.D. Solomon Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients Circulation 112 2005 3738 3744
60. D.A. Eisner, K.M. Dibb, and A.W. Trafford The mechanism and significance of the slow changes of ventricular action potential duration following a change of heart rate Exp Physiol 94 2009 520 528
61. J. Monti, J. Fischer, and S. Paskas Soluble epoxide hydrolase is a susceptibility factor for heart failure in a rat model of human disease J] Nat Genet 40 2008 529 537
62. D. Xu, N. Li, and Y. He Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors Proc Natl Acad Sci USA 103 2006 18733 18738
63. N. Li, J.Y. Liu, and V. Timofeyev Chiamvimonvat. Beneficial effects of soluble epoxide hydrolase inhibitors in myocardial infarction model: insight gained using metabolomic approaches J Mol Cell Cardiol 47 2009 835 845
64. S.N. Batchu, E. Law, and D.R. Brocks Epoxyeicosatrienoic acid prevents postischemic electrocardiogram abnormalities in an isolated heart model J Mol Cell Cardiol 46 1 2009 67 74 Jan.
65. H. Qiu, N. Li, and J.Y. Liu Soluble epoxide hydrolase inhibitors and heart failure [J] Cardiovasc Ther 23 2010 Apr
66. K.R. Chaudhary, S.N. Batchu, and D. Das Role of B-type natriuretic peptide in epoxyeicosatrienoic acid-mediated improved post-ischaemic recovery of heart contractile function [J] Cardiovasc Res 83 2 2009 Jul 15 362 370
67. G.J. Gross, K.M. Gauthier, and J. Moore Effects of the selective EET antagonist, 14,15-EEZE, on cardioprotection produced by exogenous or endogenous EETs in the canine heart Am J Physiol Heart Circ Physiol 294 6 2008 Jun H2838 H2844
68. M.P. Hutchens, T. Nakano, and J. Dunlap Soluble epoxide hydrolase gene deletion reduces survival after cardiac arrest and cardiopulmonary resuscitation Resuscitation 76 2008 89 94
69. L.G. Shewan, and A.J. Coats Ethics in the authorship and publishing of scientific articles Int J Cardiol 144 2010 1 2